New hope for rare immune disorders: upadacitinib trial launches
Disease control
Not yet recruiting
This study tests the drug upadacitinib (Rinvoq) in 30 people with rare genetic disorders that overactivate the JAK-STAT immune pathway. The trial has four phases over 12 months, including an open-label phase to find the best dose and a randomized withdrawal phase to compare the d…
Phase: PHASE1, PHASE2 • Sponsor: Lisa Satter • Aim: Disease control
Last updated Jul 03, 2026 20:17 UTC